Dublin, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The "Allergic Rhinitis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Allergic Rhinitis Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the allergic rhinitis market. A detailed picture of the allergic rhinitis pipeline landscape is provided, which includes the disease overview and allergic rhinitis treatment guidelines.

The assessment part of the report embraces in-depth allergic rhinitis commercial assessment and clinical assessment of the allergic rhinitis pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, allergic rhinitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of allergic rhinitis with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the allergic rhinitis treatment.
• Allergic rhinitis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of allergic rhinitis market.

Scope of the Report

• The allergic rhinitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and moa type for allergic rhinitis across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of allergic rhinitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• detailed allergic rhinitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across allergic rhinitis.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for allergic rhinitis.
• In the coming years, the allergic rhinitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence allergic rhinitis r&d. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the allergic rhinitis treatment market. Several potential therapies for allergic rhinitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the allergic rhinitis market size in the coming years.

Key Topics Covered

1. Report Introduction

2. Allergic Rhinitis
2.1. Overview
2.2. History
2.3. Allergic Rhinitis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Allergic Rhinitis Diagnosis
2.6.1. Diagnostic Guidelines

3. Allergic Rhinitis Current Treatment Patterns
3.1. Allergic Rhinitis Treatment Guidelines

4. Allergic Rhinitis - Analytical Perspective
4.1. In-Depth Commercial Assessment
4.1.1. Allergic Rhinitis Companies Collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Allergic Rhinitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Allergic Rhinitis Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MoA
5.1.5.1. Assessment by Stage and MoA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Allergic Rhinitis Late Stage Products (Phase-III)

7. Allergic Rhinitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-Clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Allergic Rhinitis Discontinued Products

13. Allergic Rhinitis Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of Action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Allergic Rhinitis Key Companies

15. Allergic Rhinitis Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for Being Dormant
16.2. Discontinued Products
16.2.1. Reasons for the Discontinuation

17. Allergic Rhinitis Unmet Needs

18. Allergic Rhinitis Future Perspectives

19. Allergic Rhinitis Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fnit5j

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.